The recent successful trials of monoclonal therapeutic antibodies against amyloid beta (Aβ) not only slowed symptoms but appeared to alter the biological course of Alzheimer's disease (AD), lowering pathological forms of Aβ, tau protein, and glial fibrillary acidic protein.1, 2. Here, GFAP is linked to Alzheimer disease.